Dunnett Durando, DO
Dermatology · Cape Coral, FLNPI 1275775322
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,245 of the $76,467 with a category attached, or 86.6%. Amgen accounts for 75.2% of it on its own, with 28 other manufacturers making up the rest. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $174.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$57K
- Pfizer$12K
- Johnson & Johnson$1K
- AbbVie$1K
- Sanofi$774
- Lilly USA, LLC$578
- plus $3K from 23 others
Across 1 payment — averaging $120,481 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mindera Corp$120K
What the payments were for
- Speaking & faculty fees$66,24587%
- Travel & lodging$3800%
- Food & beverage$9,35012%
- Education$4921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 70 | $57,469 |
| Pfizer | 58 | $12,247 |
| Johnson & Johnson(2 entities) | 65 | $1,423 |
| AbbVie(2 entities) | 63 | $1,092 |
| Sanofi | 23 | $774 |
| Lilly USA, LLC | 27 | $578 |
| Sun Pharmaceutical Industries Inc. | 21 | $435 |
| Mayne Pharma Commercial LLC | 17 | $321 |
| Novartis | 16 | $280 |
| LEO Pharma Inc. | 13 | $276 |
| E.r. Squibb & Sons, L.L.C. | 11 | $212 |
| Regeneron Healthcare Solutions, Inc. | 8 | $204 |
| UCB, Inc. | 6 | $189 |
| Arcutis Biotherapeutics, Inc. | 4 | $182 |
| Galderma Laboratories, L.p. | 7 | $135 |
| Boehringer Ingelheim | 4 | $114 |
| Dermavant Sciences, Inc. | 5 | $97 |
| Incyte Corporation | 3 | $68 |
| Dermira, Inc. | 3 | $63 |
| Biofrontera Inc. | 2 | $41 |
| Bristol Myers Squibb | 2 | $39 |
| Almirall LLC | 2 | $38 |
| Merz North America, Inc. | 1 | $35 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $33 |
| Clozex Medical Inc | 1 | $32 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Organon | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $21 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,467 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 30 | $403,635 |
| OtezlaApremilast | 48 | $181,766 |
| Taltz AutoinjectorIxekizumab | 22 | $150,121 |
| Dupixent SyringeDupilumab | 30 | $111,718 |
| JubliaEfinaconazole | 18 | $29,540 |
| OpzeluraRuxolitinib Phosphate | 11 | $23,989 |
| Clobetasol Propionate | 288 | $12,270 |
| Tacrolimus | 52 | $6,686 |
| Calcipotriene | 42 | $5,941 |
| Metronidazole | 76 | $4,647 |
| Doxycycline Hyclate | 95 | $4,142 |
| Ketoconazole | 294 | $4,138 |
| Triamcinolone Acetonide | 254 | $3,974 |
| Fluorouracil | 45 | $3,150 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 41 | $2,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,423 | $403,63530 claims |
| AmgenOtezla | $57,469 | $181,76648 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $33 | $29,54018 claims |
| Incyte CorporationOpzelura | $68 | $23,98911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Cape Coral
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.